Identification and optimization of pteridinone toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis

Journal of Medicinal Chemistry

Volumn 56, Issue 18, 2013, Pages 7324-7333

  Roethle, Paul A ^a   McFadden, Ryan M ^a   Yang, Hong ^a   Hrvatin, Paul ^a   Hui, Hon ^a   Graupe, Michael ^a   Gallagher, Brian ^a   Chao, Jessica ^a   Hesselgesser, Joseph ^a   Duatschek, Paul ^a   Zheng, Jim ^a   Lu, Bing ^a   Tumas, Daniel B ^a   Perry, Jason ^a   Halcomb, Randall L ^a  

^a Gilead Sciences ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 6 CHLORO 2 METHYLTHIO 5 NITROPYRIMIDINE; ALPHA INTERFERON; ANTIVIRUS AGENT; GS 9620; PTERIDINONE DERIVATIVE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CYTOKINE RELEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG SOLUBILITY; DRUG SYNTHESIS; GLYCOSYLATION; HEPATITIS B; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROGENATION; IMMUNOMODULATION; IN VIVO STUDY; MACACA FASCICULARIS; MALE; NONHUMAN; OXIDATION; PHARMACOPHORE; PHYSICAL CHEMISTRY; X RAY CRYSTALLOGRAPHY;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; MALE; MICE; MICROSOMES, LIVER; MODELS, MOLECULAR; PROTEIN CONFORMATION; PTERIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TOLL-LIKE RECEPTOR 7;

EID: 84885014914     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400815m     Document Type: Article

References (62)

1. Akira, S.; Takeda, K.; Kaisho, T. Toll-Like Receptors: Critical Proteins Linking Innate and Acquired Immunity Nat. Immunol. 2001, 2, 675-680 (Pubitemid 32747155)
2. Kawai, T.; Akira, S. The Role of Pattern-Recognition Receptors in Innate Immunity: Update on Toll-like Receptors Nat. Immunol. 2010, 11, 373-384
3. Janeway, C. A.; Medzhitoov, R. Innate Immune Recognition Annu. Rev. Immunol. 2002, 20, 197
4. Takeda, K.; Kaisho, T.; Akira, S. Toll-like Receptors Annu. Rev. Immunol. 2003, 21, 335-378
5. Beutler, B. Inferences, Questions, and Possibilities in Toll-like Receptor Signalling Nature 2004, 430, 257
6. O'Neill, L. A. After the Toll Rush Science 2004, 303, 1481
7. Kanzler, H.; Barrat, F. J.; Hessel, E. M.; Coffman, R. L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonist Nat. Med. 2007, 13, 552-559 (Pubitemid 46830615)
8. Hornung, V.; Rothenfusser, S.; Britsch, S.; Krug, A.; Jahrsörfer, B.; Giese, T.; Endres, S.; Hartmann, G. Quantitative Expression of Toll-like Receptor 1-10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligonucleotides J. Immunol. 2002, 168, 4531-4537 (Pubitemid 34441357)
9. Zarember, K. A.; Godowski, P. J. Tissue Expression of Human Toll-like Receptors and Differential Regulation of Toll-like Receptor mRNAs in Leukocytes in Response to Microbes, Their Products, and Cytokines J. Immunol. 2002, 168, 554-561 (Pubitemid 34049553)
10. Nishimura, M.; Naito, S. Tissue-Specific mRNA Expression Profiles of Human Toll-like Receptors and Related Genes Biol. Pharm. Bull. 2005, 28, 886-892 (Pubitemid 40740661)
11. Colonna, M.; Trenchieri, G.; Liu, Y.-J. Plasmacytoid Dendritic Cells: Sensing Nucleic Acids in Viral Infection and Autoimmune Disease Nat. Immunol. 2004, 5, 1219-1226
12. Lund, J. M.; Alexopoulou, L.; Sato, A.; Karow, M.; Adams, N. C.; Gale, N. W.; Iwasaki, A.; Flavell, R. A. Recognition of Single-Stranded RNA Viruses by Toll-like Receptor 7 Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 5598-5603 (Pubitemid 38481202)
13. Nishiya, T.; DeFranco, A. L. Ligand-Regulated Chimeric Receptor Approach Reveals Distinct Subcellular Localization and Signaling Properties of the Toll-like Receptors J. Biol. Chem. 2004, 279, 19008
14. O'Neill, L. A. J.; Bowie, A. G. The Family of Five: TIR Domain-Containing Adaptors in Toll-like Receptor Signaling Nat. Rev. Immunol. 2007, 7, 353-364 (Pubitemid 46674493)
15. Spyvee, M.; Hawkins, L. D.; Ishizawa, S. T. Modulators of Toll-like Receptor (TLR) Signaling Annu. Rep. Med. Chem. 2010, 45, 191-207
16. Rehermann, B.; Nascimbeni, M. The Immunology of Hepatitis B Virus and Hepatitis C Virus Infection Nat. Rev. Immunol. 2005, 5, 215-229
17. Di Bisceglie, A. M.; Hoofnagle, J. H. Optimal Therapy of Hepatitis C Hepatology (Baltimore) 2002, 36, S121-S127
18. Nature Outlook: Hepatitus C; Nature Publishing Group: London, U.K., 2011; Vol. 474; Issue 7350, Supplement, pp S1-S48.
19. Liaw, Y.-F.; Chu, C.-M. Hepatitis B Virus Infection Lancet 2009, 373, 582-592
20. Papatheodoridis, G. V.; Manolakopoulos, S.; Dusheiko, G.; Archimandritis, A. J. Therapeutic Strategies in the Management of Patients with Chronic Hepatitis B Virus Infection Lancet Infect. Dis. 2008, 8, 167-178 (Pubitemid 351249242)
21. Thomas, A.; Laxton, C.; Rodman, J.; Myangar, N.; Horscroft, N.; Parkinson, T. Investigating Toll-like Receptor Agonists for Potential To Treat Hepatitis C Virus Infection Antimicrob. Agents Chemother. 2007, 51, 2969
22. Isogawa, M.; Robek, M. D.; Furuichi, Y.; Chisari, F. V. Toll-like Receptor Signaling Inhibits Hepatitis B Virus Replication In Vivo J. Virol. 2005, 79, 7269-7272 (Pubitemid 40677357)
23. Kwon, H.; Lok, A. S. Hepatitis B therapy Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 275-284
24. Alazawi, W.; Foster, G. R. Advances in the Diagnosis and Treatment of Hepatitis B Curr. Opin. Infect. Dis. 2008, 21, 508-515
25. Brunetto, M. R.; Moriconi, F.; Bonino, F.; Lau, G. K. K.; Farci, P.; Yurdaydin, C.; Piratvisuth, T.; Luo, K.; Wang, Y.; Hadziyannis, S.; Wolf, E.; McCloud, P.; Batrla, R.; Marcellin, P. Hepatitis B Virus Surface Antigen Levels: A Guide to Sustained Response to Peginterferon alfa-2a in HBeAg-Negative Chronic Hepatisis B Hepatology 2009, 49, 1141-1150
26. Moucari, R.; Mackiewicz, V.; Lada, O.; Ripault, M.-P.; Castelnau, C.; Martinot-Peignoux, M.; Dauvergne, A.; Asselah, T.; Boyer, N.; Bedossa, P.; Valla, D.; Vidaud, M.; Nicolas-Chanoine, M.-H.; Marcellin, P. Early Serum HBsAg Drop: A Strong Predictor of Sustanined Virological Response to Pegylated Interferon Alfa-2a in HBeAg-Negative Patients Hepatology 2009, 49, 1151-1157
27. Buster, E. H.; Flink, H. J.; Cakaloglu, Y.; Simon, K.; Trojan, J.; Tabak, F.; So, T. M.; Feinman, S. V.; Mach, T.; Akarca, U. S.; Schutten, M.; Tielemans, W.; van Vuuren, A. J.; Hansen, B. E.; Janssen, H. L. Sustained HBeAg and HBsAg Loss after Long-Term Follow-Up of HBeAg-Positive Patients Treated with Peginterferon alpha-2b Gastroenterology 2008, 135, 459-467
28. Reitz, A. B.; Goodman, M. G.; Pope, B. L.; Argentieri, D. C.; Bell, S. C.; Burr, L. E.; Chourmouzis, E.; Come, J. C.; Goodman, J. H.; Klaubert, D. H.; Maryanoff, B. E.; McDonnel, M. E.; Rampulla, M. S.; Schott, M. R.; Chen, R. Small Molecule Immunostimulants. Synthesis and Activity of 7,8-Disubstututed Guanosines and Structurally Related Compounds J. Med. Chem. 1994, 37, 3561-3578 (Pubitemid 24334612)
29. Nagahara, K.; Anderson, J. D.; Kini, G. D.; Dalley, N. K.; Larson, S. B.; Smee, D. F.; Jin, A.; Sharma, B. S.; Jolley, W. B.; Robins, R. K.; Cottam, H. B. Thiazolo[4,5-d ]pyrimidine Nucleosides. The Synthesis of Certain 3-β-d -Ribofuranosylthiazolo[4,5- d ]pyrimidines as Potential Immunotherapeutic Agents J. Med. Chem. 1990, 33, 407-415 (Pubitemid 20038224)
30. Horsmans, Y.; Berg, T.; Desager, J.-P.; Mueller, T.; Schott, E.; Fletcher, S.; Steffy, K. R.; Bauman, L. A.; Kerr, B. M.; Averett, D. R. Isatoribine, an Agonist of TLR7, Reduces Plasma Virus Concentration in Chronic Hepatitis C Infection Hepatol. 2005, 42, 724-731 (Pubitemid 41233667)
31. Fletcher, S.; Steffy, K.; Averett, D. Masked Oral Prodrugs of Toll-like Receptor 7 Agonists: A New Approach for the Treatment of Infectious Disease Curr. Opin. Invest. Drugs 2006, 7, 702-708 (Pubitemid 44263174)
32. Xiang, A. X.; Webber, S. E.; Kerr, B. M.; Ruiden, E. J.; Lennox, J. R.; Haley, G. J.; Wang, T.; Ng, J. S.; Herbert, M. R.; Clark, D. L.; Bahn, V. N.; Li, W.; Fletcher, S. P.; Steffy, K. R.; Bartkowski, D. M.; Kirdovsky, L. I.; Bauman, L. A.; Averett, D. R. Discovery of ANA975: An Oral Prodrug of the TLR7 Agonist Isatoribine Nucleosides, Nucleotides Nucleic Acids 2007, 26, 625-640
33. Bergmann, J. F.; de Bruijne, J.; Hotho, D. M.; de Knegt, R. J.; Boonstra, A.; Weegink, C. J.; van Vliet, A. A.; van de Wetering, J.; Fletcher, S. P.; Bauman, L. A.; Rahimy, M.; Appleman, J. R.; Freddo, J. L.; Janssen, H. L. A.; Reesink, H. W. Randomized Clinical Trial: Anti-Viral Activity of ANA773, an Oral Inducer of Endogenous Interferons Acting via TLR7, in Chronic HCV Aliment. Pharmacol. Ther. 2011, 34, 443-453
34. Boonstra, A.; Liu, B.-S.; Groothuismink, Z. M. A.; Bergmann, J. F.; de Bruijne, J.; Hotho, D. M.; Hansen, B. E.; van Vliet, A. A.; van de Wetering de Rooij, J.; Fletcher, S. P.; Bauman, L. A.; Rahimy, M.; Appleman, J. R.; Freddo, J. L.; Reesink, H. W.; de Knegt, R. J.; Janssen, H. L. A. Potent Immune Activation in Chronic Hepatitis C Patients upon Administration of an Oral Inducer of Endogenous Interferons That Acts via Toll-like Receptor 7 Antiviral Ther. 2012, 17, 657-667
35. Nirota, K.; Kazaoka, K.; Niimoto, I.; Kumihara, H.; Sajiki, H.; Isobe, Y.; Takaku, H.; Tobe, M.; Ogita, H.; Ogino, T.; Ichii, S.; Kurimoto, A.; Kawakami, H. Discovery of 8-Hydroxyadenines as a Novel Type of Interferon Inducer J. Med. Chem. 2002, 45, 5419
36. Hirota, K.; Kazaoka, K.; Sajiki, H. Synthesis and Biological Evaluation of 2,8-Disubstutited 9-Benzyladenines: Discovery of 8-Mercaptoadenines as Potent Interferon Inducers Bioorg. Med. Chem. 2003, 11, 2715-2722 (Pubitemid 36682995)
37. Isobe, Y.; Tobe, M.; Ogita, H.; Kurimoto, A.; Ogino, T.; Kawakami, H.; Takaku, H.; Sajiki, H.; Hirota, K.; Hayashi, H. Synthesis and Structure-Activity Relationships of 2-Substituted-8-Hydroxyadenine Derivatives as Orally Available Interferon Inducers without Emetic Side Effects Bioorg. Med. Chem. 2003, 11, 3641-3647 (Pubitemid 36952262)
38. Kurimoto, A.; Ogino, T.; Ichii, S.; Isobe, Y.; Tobe, M.; Ogita, H.; Takaku, H.; Sajiki, H.; Hirota, K.; Kawakami, H. Synthesis and Evaluation of 2-Substituted 8-Hydroxyadenines as Potent Interferon Inducers with Improved Oral Bioavailabilities Bioorg. Med. Chem. 2004, 12, 1091-1099 (Pubitemid 38251300)
39. Kurimoto, A.; Ogino, T.; Ichii, S.; Isobe, Y.; Tobe, M.; Ogita, H.; Takaku, H.; Sajiki, H.; Hirota, K.; Kawakami, H. Synthesis and Structure-Activity Relationships of 2-Amino-8-hydroxyadenines as Orally Active Interferon Inducing Agents Bioorg. Med. Chem. 2003, 11, 5501-5508 (Pubitemid 37464677)
40. Isobe, Y.; Kurimoto, A.; Tobe, M.; Hashimoto, K.; Nakamura, T.; Norimura, K.; Ogita, H.; Takaku, H. Synthesis and Biological Evaluation of Novel 9-Substituted-8-Hydroxyadenine Derivatives as Potent Interferon Inducers J. Med. Chem. 2006, 49, 2088-2095
41. Gerster, J. F.; Lindstrom, K. J.; Miller, R. L.; Tomai, M. A.; Birmachu, W.; Bomersine, S. N.; Gibson, S. J.; Imbertson, L. M.; Jacobson, J. R.; Knafla, R. T.; Maye, P. V.; Nikolaides, N.; Oneyemi, F. Y.; Parkhurst, G. J.; Pecore, S. E.; Reiter, M. J.; Scribner, L. S.; Testerman, T. L.; Thompson, N. J.; Wagner, T. L.; Weeks, C. E.; Andre, J.-D.; Lagain, D.; Bastard, Y.; Lupu, M. Synthesis and Structure-Activity-Relationships of 1 H -Imidazo[4.5- c ]quinolines That Induce Interferon J. Med. Chem. 2005, 48, 3481-3491 (Pubitemid 40664100)
42. Garland, S. M. Imiquimod Curr. Opin. Infect. Dis. 2003, 16, 85-89 (Pubitemid 36521020)
43. Lee, J.; Chuang, T.; Redecke, V.; She, L.; Pitha, P. M.; Carson, D. A.; Raz, E.; Cottam, H. B. Molecular Basis for the Immunostimulatory Activity of Guanine Nucleoside Analogs: Activation of Toll-like Receptor 7 Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 6646
44. Hemmi, H.; Kaisho, T.; Takeuchi, O.; Sato, S.; Sanjo, H.; Hoshino, K.; Horiuchi, T.; Tomizawa, H.; Takeda, K.; Akira, S. Small Anti-Viral Compounds Activate Immune Cells via the TLR7 MyD88-Dependent Signaling Pathway Nat. Immunol. 2002, 3, 196-200 (Pubitemid 34141451)
45. Pryde, D. C.; Tran, T.-D.; Jones, P.; Parsons, G. C.; Bish, G.; Adam, F. M.; Smith, M. C.; Middleton, D. S.; Smith, N. N.; Calo, F.; Hay, D.; Paradowski, M.; Proctor, K. J. W.; Parkinson, T.; Laxton, C.; Fox, D. N. A.; Horscroft, N. J.; Ciaramella, G.; Jones, H. M.; Duckworth, J.; Benson, N.; Harrison, A.; Webster, R. The Discovery of a Novel Prototype Small Molecule TLR7 Agonist for the Treatment of Hepatitic C Virus Infection Med. Chem. Commun. 2011, 2, 185-189
46. Jones, P.; Pryde, D. C.; Tran, T.-D.; Adam, F. M.; Bish, G.; Calo, F.; Ciaramella, G.; Dixon, R.; Duckworth, J.; Fox, D. N. A.; Hay, D. A.; Hitchin, J.; Horscroft, N.; Howard, M.; Laxton, C.; Parkinson, T.; Parsons, G.; Proctor, K.; Smith, M. C.; Smith, N.; Thomas, A. Discovery of a Highly Potent Series of TLR7 Agonists Bioorg. Med. Chem. Lett. 2011, 21, 5939-5943
47. Tran, T.-D.; Pryde, D. C.; Jones, P.; Adam, F. M.; Benson, N.; Bish, G.; Calo, F.; Ciaramella, G.; Dixon, R.; Duckworth, J.; Fox, D. N. A.; Hay, D. A.; Hitchin, J.; Horscroft, N.; Howard, M.; Gardner, I.; Jones, H. M.; Laxton, C.; Parkinson, T.; Parsons, G.; Proctor, K.; Smith, M. C.; Smith, N.; Thomas, A. Design and Optimization of Orally Active TLR7 Agonists for the Treatment of Hepatitis C Virus Infection Bioorg. Med. Chem. Lett. 2011, 21, 2389-2393
48. Alternate scaffold: Fidock, M. D.; Souberbielle, B. E.; Laxton, C.; Rawal, J.; Delphuech-Adams, O.; Corey, T. P.; Colman, P.; Kumar, V.; Cheng, J. B.; Wright, K.; Srinivasan, S.; Rana, K.; Craig, C.; Horscroft, N.; Perros, M.; Westby, M.; Webster, R.; van der Ryst, E. The Innate Immune Response, Clinical Outcomes, and ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691) Clin. Pharmacol. Ther. 2011, 89, 821-829
49. Oligoribonucleotides have also been reported: Lan, T.; Wang, D.; Zhu, F. G.; Kandimalla, E. R.; Agrawal, S. Toll-like Receptor 7 Selective Synthetic Oligoribonucleotide Agonists: Synthesis and Structure-Activity Relationship Studies J. Med. Chem. 2009, 52, 6871-6879
50. Lan, T.; Bhagat, L.; Wang, D.; Dai, M.; Kandimalla, E. R.; Agrawal, S. Synthetic Oligoribonucleotides Containing Arabinonucleotides Act as Agonists of TLR7 and 8 Biorg. Med. Chem. Lett. 2009, 19, 2044-2047
51. Lan, T.; Kandimalla, E. R. Synthesis, Purification, and Characterization of Oligoribonucleotides That Act as Agonists of TLR7 and/or TLR8 Methods Mol. Biol. 2011, 764, 249-261
52. Jurk, M.; Heil, F.; Vollmer, J.; Schetter, C.; Kreig, A. M.; Wagner, H.; Lipford, G.; Bauer, S. Human TLR7 or TLR8 Independently Confer Responsiveness to the Antiviral Compound R-848 Nat. Immunol. 2002, 3, 499 (Pubitemid 34669818)
53. Tanji, H.; Ohto, U.; Shibata, T.; Miyake, K.; Shimizu, T. Structural Reorganization of the Toll-like Receptor 8 Dimer Induced by Agonistic Ligands Science 2013, 339, 1426
54. Prime, version 3.1; Schrödinger, LLC: New York, NY, 2012.
55. Macromodel, version 9.9; Schrödinger, LLC: New York, NY, 2012.
56. d'Atri, G.; Gomarasca, P.; Resnati, G.; Tronconi, G.; Scolastico, C.; Sirtori, C. R. Novel Pyrimidine and 1,3,5-Triazine Hypolipemic Agents J. Med. Chem. 1984, 27, 1621-1629 (Pubitemid 15177903)
57. Previous example of pteridine-dione compounds: Breault, G. A.; Comita-Prevoir, J.; Eyermann, C. J.; Geng, B.; Petrichko, R.; Doig, P.; Gorseth, E.; Noonan, B. Exploring 8-Benzyl Pteridine-6,7-diones as Inhibitors of Glutamate Racemase (MurI) in Gram-Positive Bacteria Biorg. Med. Chem. Lett. 2008, 18, 6100-6103
58. Lanford, R. E.; Guerra, B.; Chavez, D.; Giavedoni, L.; Hodara, V. L.; Brasky, K. M.; Fosdick, A.; Frey, C. R.; Zheng, J.; Wolfgang, G.; Halcomb, R. L.; Tumas, D. B. GS-9620, an Oral Agonist of Toll-like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees Gastroenterology 2013, 144, 1508-1517
59. Menne, S.; Tennant, B. C.; Liu, K. H.; Ascenzi, M. A.; Baldwin, B. H.; Bellezza, C. A.; Cote, P. J.; Zheng, X.; Wolfgang, G.; Tumas, D. Anti-Viral Efficacy and Induction of an Antibody Response against Surface Antigen with the TLR7 Agonist GS-9620 in the Woodchuck Model of Chronic HBV Infection J. Hepatol. 2011, 54, S441
60. Lopatin, U.; Wolfgang, G.; Tumas, D.; Frey, C. R.; Ohmstede, C.; Hesselgesser, J.; Kearney, B.; Moorehead, L.; Subramanian, G. M.; McHutchison, J. G. Safety, Pharmacokinetics and Pharmacodynamics of GS-9620, an Oral Toll-like Receptor 7 Agonist Antiviral Ther. 2013, 18, 409-418
61. Halcomb, R. L.; Roethle, P.; Yang, H.; McFadden, R.; Hrvatin, P.; Hui, H.; Graupe, M.; Tumas, D.; Zheng, X.; Lu, B.; Perry, J.; Duatschek, P.; Hesselgesser, J.; Graupe, D.; Li, B. Discovery of GS-9620, an Oral agonist of Toll-like Receptor 7 for the Treatment of Chronic Hepatitis B and C Infection. Abstracts of Papers, 243rd National Meeting and Exposition of the American Chemical Society, San Diego, CA, United States, March 25-29, 2012; American Chemical Society: Washington, DC, 2012; MEDI-22.
62. Tumas, D.; Fosdick, A.; Zheng, X.; Lanford, R.; Hesselgesser, J.; Frey, C.; Wolfgang, G.; Halcomb, R.; Lopatin, U. GS-9620 Induced a Presystemic Innate Immune Response in the Absence of Serum Interferon or Adverse Effects in Both Non-Clinical Species and Humans J. Hepatol. 2011, 54 (Suppl. 1) S446-S447